Common use of High Interest Targets Clause in Contracts

High Interest Targets. Under the Neurological Disease Research Plan, Biogen will establish a prioritized list of Neurology Targets that are designated by Biogen as high interest targets and added to such list in accordance with Section 1.2.3(b), which Neurology Targets, in accordance with Section 1.2.3(b)(v), may include one or more gene targets that are already defined as “High Interest Targets” or “Collaboration Targets” under the Neurology II Agreement using a different Strategy directed to such High Interest Target or Collaboration Target than the approach to such gene target being pursued under the Neurology II Agreement (each such target, a “High Interest Target” and such list the “High Interest Target List”). With respect to the High Interest Target List (i) at any given time during the Research Term such list may not include more than [***] High Interest Targets for which at least one Strategy directed to such High Interest Target has not achieved Target Sanction, and (ii) no targets may be added to the High Interest Target List unless target validation activities for the applicable Strategies directed to such targets can reasonably be completed before the expiration of the Research Term, taking into account the target validation activities already being conducted under the Neurological Disease Research Program under Section 1.2.3(d) and the number of FTEs available to perform activities as described in Section 1.11. Without limiting the foregoing, if, on or after the [***] anniversary of the date a High Interest Target was added to the High Interest Target List, such target remains or becomes an Inactive Target, then, unless the Parties mutually agree through the Neurology JRC that such High Interest Target may remain on the High Interest Target List, such High Interest Target shall automatically be removed from the High Interest Target List and will no longer be a High Interest Target. However, during the remainder of the Research Term, such target will remain a Neurology Target and Biogen may again add such target to the High Interest Target List in accordance with this Section 1.2.3(a).

High Interest Targets. Under the Neurological Disease Research Plan, Biogen Idec will establish a prioritized list of Neurology Targets, including ALS Targets that are designated by Biogen to designate as high interest targets and added to such list in accordance with Section 1.2.3(b), which Neurology Targets, in accordance with Section 1.2.3(b)(v), may include one or more gene targets that are already defined as “High Interest Targets” or “Collaboration Targets” under the Neurology II Agreement using a different Strategy directed to such High Interest Target or Collaboration Target than the approach to such gene target being pursued under the Neurology II Agreement (each such target, a “High Interest Target” and such list the “High Interest Target List”). With respect The number of High Interest Targets cannot exceed [***]. The initial High Interest Target List has been mutually agreed upon by the Parties in writing on or prior to the Effective Date. Biogen Idec will present updates, if any, to the High Interest Target List at each meeting of the Neurology JRC. Each Neurology Target added to the High Interest Target List will be a High Interest Target; provided however, that if Isis notifies Biogen Idec within [***] days after the date on which Isis receives a High Interest Target List containing a new High Interest Target that (i1) [***], (2) such gene target is not eligible to become a High Interest Target hereunder [***], or (3) such gene target is [***], then the applicable gene target will not be a High Interest Target hereunder. When Biogen Idec adds a Neurology Target to the High Interest Target List, Biogen Idec will identify on the High Interest Target List if Biogen Idec intends such target to be an ALS Target. Biogen Idec may convert an ALS Target into a High Interest Target that is not an ALS Target at any given time during meeting of the Research Term Neurology JRC. For clarity, Biogen Idec may add any Isis Neurology Target to the High Interest Target List so long as such list may not include Isis Neurology Target is more than [***] High Interest Targets months away from the date on which Isis in good faith believes [***]. In addition, once target validating activities for which at least one Strategy directed to such a High Interest Target has not achieved Target Sanction, and (ii) no targets may be added to the High Interest Target List unless target validation activities for the applicable Strategies directed to such targets can reasonably be completed before the expiration of the Research Term, taking into account the target validation activities already being conducted have been initiated under the Neurological Disease Research Program under Section 1.2.3(d) and Plan or by Isis independently (as presented by Isis to the number of FTEs available to perform activities as described in Section 1.11. Without limiting the foregoingNeurology JRC), if, on or after the [***] anniversary of the date Biogen Idec may not remove a High Interest Target was added to the High Interest Target List, such target remains or becomes an Inactive Target, then, unless the Parties mutually agree through the Neurology JRC that such High Interest Target may remain on the High Interest Target List, such High Interest Target shall automatically be removed from the High Interest Target List and will no longer be a High Interest Target. However, during the remainder of the Research Term, such target will remain a Neurology Target and Biogen may again add such target to the High Interest Target List in accordance with this Section 1.2.3(a)until [***].

High Interest Targets. Under the Neurological Disease Research Plan, Biogen will establish a prioritized list of Neurology Targets, including ALS Targets that are designated by Biogen to designate as high interest targets and added to such list in accordance with Section 1.2.3(b), which Neurology Targets, in accordance with Section 1.2.3(b)(v), may include one or more gene targets that are already defined as “High Interest Targets” or “Collaboration Targets” under the Neurology II Agreement using a different Strategy directed to such High Interest Target or Collaboration Target than the approach to such gene target being pursued under the Neurology II Agreement (each such target, a “High Interest Target” and such list the “High Interest Target List”). With respect The number of High Interest Targets cannot exceed [***]. The initial High Interest Target List has been mutually agreed upon by the Parties in writing on or prior to the Effective Date. Biogen will present updates, if any, to the High Interest Target List at each meeting of the Neurology JRC. Each Neurology Target added to the High Interest Target List will be a High Interest Target; provided, however, that if Ionis notifies Biogen within [***] days after the date on which Ionis receives a High Interest Target List containing a new High Interest Target that (i1) [***], (2) such gene target is not eligible to become a High Interest Target hereunder [***], or (3) such gene target is [***], then the applicable gene target will not be a High Interest Target hereunder. When Biogen adds a Neurology Target to the High Interest Target List, Biogen will identify on the High Interest Target List if Biogen intends such target to be an ALS Target. Biogen may convert an ALS Target into a High Interest Target that is not an ALS Target at any given time during meeting of the Research Term Neurology JRC. For clarity, Biogen may add any Ionis Neurology Target to the High Interest Target List so long as such list may not include Ionis Neurology Target is more than [***] High Interest Targets months away from the date on which Ionis in good faith believes [***]. In addition, once target validating activities for which at least one Strategy directed to such a High Interest Target has not achieved Target Sanction, and (ii) no targets may be added to the High Interest Target List unless target validation activities for the applicable Strategies directed to such targets can reasonably be completed before the expiration of the Research Term, taking into account the target validation activities already being conducted have been initiated under the Neurological Disease Research Program under Section 1.2.3(d) and Plan or by Ionis independently (as presented by Ionis to the number of FTEs available to perform activities as described in Section 1.11. Without limiting the foregoingNeurology JRC), if, on or after the [***] anniversary of the date Biogen may not remove a High Interest Target was added to the High Interest Target List, such target remains or becomes an Inactive Target, then, unless the Parties mutually agree through the Neurology JRC that such High Interest Target may remain on the High Interest Target List, such High Interest Target shall automatically be removed from the High Interest Target List until [***]. The Parties acknowledge and will no longer agree that, as of August 4, 2014, [***] has been designated as a Collaboration Target that is an ALS Target under this Agreement. The Parties further acknowledge and agree that (a) notwithstanding any scientific determination regarding [***], the ALS Collaboration Program for [***] shall be treated as an ALS Collaboration Program that is not a [***] Collaboration Program for purposes of this Agreement, (b) [***] is not a Multi-Indication Target (as defined below) and (c) [***] is deemed to be a High Interest Target. However, during the remainder Pre-Existing Target (as defined below) for purposes of the Research Term, such target will remain a Neurology Target and Biogen may again add such target to the High Interest Target List in accordance with this Section 1.2.3(a)Agreement.

High Interest Targets. Under the Neurological Disease Research Plan, Biogen will establish a prioritized list of Neurology Targets, including ALS Targets that are designated by Biogen to designate as high interest targets and added to such list in accordance with Section 1.2.3(b), which Neurology Targets, in accordance with Section 1.2.3(b)(v), may include one or more gene targets that are already defined as “High Interest Targets” or “Collaboration Targets” under the Neurology II Agreement using a different Strategy directed to such High Interest Target or Collaboration Target than the approach to such gene target being pursued under the Neurology II Agreement (each such target, a “High Interest Target” and such list the “High Interest Target List”). With respect The number of High Interest Targets cannot exceed [***]. The initial High Interest Target List has been mutually agreed upon by the Parties in writing on or prior to the Effective Date. Biogen will present updates, if any, to the High Interest Target List (i) at any given time during each meeting of the Research Term such list may not include more than [***] High Interest Targets for which at least one Strategy directed to such High Interest Neurology JRC. Each Neurology Target has not achieved Target Sanction, and (ii) no targets may be added to the High Interest Target List unless target validation activities for the applicable Strategies directed to such targets can reasonably will be completed before the expiration of the Research Terma High Interest Target; provided, taking into account the target validation activities already being conducted under the Neurological Disease Research Program under Section 1.2.3(d) and the number of FTEs available to perform activities as described in Section 1.11. Without limiting the foregoinghowever, if, on or after the that if Ionis notifies Biogen within [***] anniversary of days after the date on which Ionis receives a High Interest Target was added List containing a new High Interest Target that (i) [***], (ii) such gene target is not eligible to become a High Interest Target hereunder [***], or (iii) such gene target is [***], then the applicable gene target will not be a High Interest Target hereunder. When Biogen adds a Neurology Target to the High Interest Target List, such target remains or becomes an Inactive Target, then, unless the Parties mutually agree through the Neurology JRC that such High Interest Target may remain Biogen will identify on the High Interest Target List, List if Biogen intends such target to be an ALS Target. Biogen may convert an ALS Target into a High Interest Target shall automatically be removed that is not an ALS Target at any meeting of the Neurology JRC. For clarity, Biogen may add any Ionis Neurology Target to the High Interest Target List until such Ionis Neurology Target is less than [***] months away from the date on which Ionis in good faith believes [***]. In addition, once target validating activities for a High Interest Target have been initiated under the Neurological Disease Research Plan or by Ionis independently (as presented by Ionis to the Neurology JRC), Biogen may not remove a High Interest Target from the High Interest Target List until [***]. The Parties acknowledge and will no longer agree that, as of August 4, 2014, [***] has been designated as a Collaboration Target that is an ALS Target under this Agreement. The Parties further acknowledge and agree that (1) notwithstanding any scientific determination regarding [***], the ALS Collaboration Program for [***] shall be treated as an ALS Collaboration Program that is not a [***] Collaboration Program for purposes of this Agreement, (2) [***] is not a Multi-Indication Target (as defined below) and (3) [***] is deemed to be a High Interest Target. However, during the remainder Pre-Existing Target (as defined below) for purposes of the Research Term, such target will remain a Neurology Target and Biogen may again add such target to the High Interest Target List in accordance with this Section 1.2.3(a)Agreement.